Compare GORO & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GORO | GANX |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.1M | 159.2M |
| IPO Year | 2010 | 2021 |
| Metric | GORO | GANX |
|---|---|---|
| Price | $1.67 | $1.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $1.75 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 10.5M | 546.5K |
| Earning Date | 04-16-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.95 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $65,726,000.00 | $55,180.00 |
| Revenue This Year | $9.04 | N/A |
| Revenue Next Year | $93.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $1.41 |
| 52 Week High | $1.87 | $4.34 |
| Indicator | GORO | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 60.38 | 40.39 |
| Support Level | $1.54 | $1.67 |
| Resistance Level | $1.70 | $1.86 |
| Average True Range (ATR) | 0.13 | 0.13 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 86.48 | 54.05 |
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.